PulmonologyaCT1 Inhalation Solution

An aCT1 inhalation solution has demonstrated efficacy in protecting the lung from injury in different disease states. Xequel Bio’s aCT1 inhalation solution is in the preclinical stage, for use in the treatment of acute lung injury/acute respiratory distress syndrome and SARS-CoV-2 induced lung injury. With few to no treatments available to protect lung tissue from the damage caused by these disease states, Xequel Bio’s innovation has the potential to provide relief to those in need.

  • Acute And Chronic
    Lung Injury
    Acute Lung Injury/
    Acute Respiratory
    Distress Syndrome
  • Acute And Chronic
    Lung Injury
    SARS-CoV-2
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA